Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2037
Abstract: Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with… read more here.
Keywords: egfr mutated; mutated non; non small; cancer ... See more keywords
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-022-02128-6
Abstract: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). Serial plasma samples were collected from… read more here.
Keywords: egfr driven; patients egfr; egfr mutated; concentration egfr ... See more keywords
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01147-w
Abstract: Objectives: The study was designed to investigate the safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non–small cell lung cancer (NSCLC) and asymptomatic brain metastases, a patient subgroup… read more here.
Keywords: brain metastases; egfr mutated; asymptomatic brain; erlotinib osimertinib ... See more keywords
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00657-1
Abstract: The first (1G) and second (2G) generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show differential inhibitory capacities towards EGFR T790M-mutated non-small-cell lung cancer (NSCLC) cells. To assess the ratio of the… read more here.
Keywords: egfr mutated; egfr; acquired t790m; efficacy osimertinib ... See more keywords
Dual-responsive nanosystem for precise molecular subtyping and resistant reversal of EGFR targeted therapy
Sign Up to like & getrecommendations! Published in 2019 at "Chemical Engineering Journal"
DOI: 10.1016/j.cej.2019.04.140
Abstract: Abstract The clinical outcome of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is limited by the ambiguous molecular subtypes of non-small cell lung cancer (NSCLC) patients and the emergence of drug-resistance. Here, a nanotheranostic… read more here.
Keywords: responsive nanosystem; egfr; mutated nsclc; dual responsive ... See more keywords
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.07.003
Abstract: The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly changed over the last decade with the clinical introduction of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the discovery of… read more here.
Keywords: generation egfr; egfr mutated; egfr; egfr tkis ... See more keywords
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.102820
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer (NSCLC) patients. Nonetheless, acquired resistance develops within 10-14 months and 20-30% of EGFR-mutated… read more here.
Keywords: egfr tkis; egfr mutated; combination egfr; tkis chemotherapy ... See more keywords
Factors affecting outcome in resected EGFR-mutated lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2066984
Abstract: Abstract Introduction Long-term data on disease trajectory of EGFR-mutated early-stage non-small cell lung cancer (NSCLC) is still limited. This is relevant in the context of the recently approved introduction of adjuvant EGFR-targeting therapy, specifically osimertinib… read more here.
Keywords: lung cancer; lung; recurrence; egfr mutated ... See more keywords
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2132116
Abstract: Abstract Background Osimertinib is a recently approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. The aim of the present meta-analysis was to investigate the… read more here.
Keywords: meta analysis; osimertinib; safety osimertinib; patients egfr ... See more keywords
Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz257.012
Abstract: Abstract Background Liquid biopsy is a minimally invasive strategy to detect genetic alterations in non-small cell lung cancer (NSCLC) patients. In particular, it is clinically useful for the detection of the EGFR T790M resistance mutation… read more here.
Keywords: egfr mutated; sputum; plasma sputum; nsclc patients ... See more keywords
Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001527
Abstract: Rearranged during transfection (RET) fusions and epidermal growth factor receptor (EGFR) mutations are potent oncogenic drivers in patients with nonsmall cell lung cancer (NSCLC), but rarely co-exist. Concurrent RET/EGFR mutations have been reported in patients… read more here.
Keywords: egfr mutated; lung; ret fusion; egfr ... See more keywords